Group 1 - Jiuyuan Gene (02566) saw a nearly 24% increase in stock price, reaching HKD 15.28 with a trading volume of HKD 41.215 million [1] - The company plans to hold a board meeting on August 18 to approve its interim results, which is a significant upcoming event [1] - Jiuyuan Gene is focused on the development of the first domestic biosimilar of Semaglutide, with weight loss indications expected to be submitted for market approval in the first half of 2026 [1] Group 2 - The company aims to strengthen its market presence by enhancing its hospital market advantages and expanding accessibility through pharmacy networks and e-commerce partnerships [1] - Jiuyuan Gene has granted overseas rights for Semaglutide to other domestic pharmaceutical companies, including exclusive licensing agreements with Kexing Bio for major Latin American countries and Fosun Pharma for various regions including the Middle East and parts of Africa [1] - New drug applications for Semaglutide are expected to be submitted in Brazil and Saudi Arabia by 2025 [1]
港股异动 | 九源基因(02566)尾盘涨近24% 将于下周一发布业绩 预计年内向巴西等递交司美格鲁肽新药申请